Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Baxter's TricOs orthobiologic:

This article was originally published in Clinica

Executive Summary

The FDA has given Baxter Healthcare 510(k) clearance to market its first orthobiologic product in the US. The TricOs T bone void filler is indicated for use in voids in bone that are not intrinsic to the stability of the bony structure, including bone defects from surgery or traumatic injury. Full US market availability of the product should occur in the second half of 2006, said the Deerfield, Illinois firm.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT050598

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel